New Blood Filter Treatment Shows Promise for Managing Preeclampsia

Preeclampsia, a serious pregnancy complication marked by high blood pressure and organ damage, affects 3% to 8% of pregnancies worldwide. For decades, the only definitive treatment has been delivering the baby—often prematurely—leaving mothers and infants at risk. Now, a small but promising clinical trial suggests a new approach: filtering a harmful protein from the bloodstream to safely extend pregnancies and reduce complications.

Blood Filtering Shows Early Promise in Pilot Trial

A pilot study published on April 27, 2026, in Science News tested a blood-filtering technique in 16 women diagnosed with severe early-onset preeclampsia. The treatment targets soluble fms-like tyrosine kinase-1 (sFlt-1), a protein that disrupts blood vessel function and drives the condition’s progression. By removing excess sFlt-1 from the bloodstream, researchers observed modest reductions in blood pressure and, in some cases, prolonged pregnancies by several days to weeks.

“What we have is the first time anyone has developed a targeted treatment for preeclampsia,” said Ravi Thadhani, the study’s lead author and executive vice president of clinical affairs at Cedars-Sinai Medical Center. While the results are preliminary, they offer hope for a condition that currently lacks medical interventions beyond early delivery.

How the Treatment Works

Preeclampsia typically emerges after the 20th week of pregnancy and can escalate rapidly, leading to seizures (eclampsia), stroke, or organ failure. The condition is linked to an imbalance of angiogenic factors—proteins that regulate blood vessel growth. SFlt-1, in particular, binds to and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), both critical for maintaining healthy blood vessels during pregnancy.

The blood-filtering device used in the trial employs antibodies to selectively remove sFlt-1 from the bloodstream, similar to dialysis for kidney disease. Participants underwent one to three filtering sessions, with researchers monitoring blood pressure, protein levels in urine (a marker of kidney damage), and fetal well-being. While the study was not designed to measure long-term outcomes, the treatment appeared safe and did not trigger adverse effects in mothers or babies.

Why This Matters

Premature birth is the leading cause of infant mortality and long-term disabilities, and preeclampsia is a primary driver. In the U.S., the condition accounts for 15% of preterm deliveries, with infants born before 34 weeks facing heightened risks of respiratory distress, developmental delays, and other complications. For mothers, preeclampsia increases the lifetime risk of cardiovascular disease, including hypertension and stroke.

“The ability to delay delivery even by a few days can significantly improve neonatal outcomes,” said Thadhani. “Every extra day in the womb allows the baby’s lungs and brain to develop further.” In the trial, some women gained an additional 5 to 14 days of gestation, though the sample size was too small to draw definitive conclusions about efficacy.

Limitations and Next Steps

The study’s small scale and lack of a control group mean the findings must be interpreted cautiously. Larger, randomized trials are needed to confirm whether blood filtering can consistently extend pregnancies without harm and to determine the optimal timing and frequency of treatment. Researchers also noted that the technique may not be suitable for all preeclampsia cases, particularly those with advanced organ damage or very early-onset disease.

“This is a proof-of-concept study,” Thadhani emphasized. “We’re not suggesting this is a cure, but it’s a step toward a targeted therapy where none currently exists.”

Other Emerging Treatments on the Horizon

The blood-filtering trial is one of several experimental approaches under investigation. At the Medical College of Wisconsin, researchers are testing MitoQ, an antioxidant supplement aimed at improving vascular function in preeclampsia patients. Funded by a Gates Foundation grant, the trial seeks to address the root causes of the condition by reducing oxidative stress in blood vessels.

“There is currently no medication that can cure preeclampsia or even hold it at bay,” said Jennifer McIntosh, a maternal-fetal medicine specialist leading the MitoQ study. “The only definitive treatment is delivery, which often means the newborn ends up in intensive care.” Early results from the trial are expected later this year.

What So for Pregnant Women

For now, the standard of care for preeclampsia remains unchanged: close monitoring, blood pressure management with medications like labetalol or nifedipine, and timely delivery when risks outweigh the benefits of continuing the pregnancy. Women with a history of preeclampsia or risk factors such as chronic hypertension, diabetes, or obesity should discuss preventive strategies with their healthcare providers, including low-dose aspirin starting in the first trimester.

While the blood-filtering technique is not yet available outside clinical trials, the early results underscore the urgent need for innovative treatments. “Preeclampsia is a complex disease, and it’s unlikely that any single therapy will work for everyone,” said Thadhani. “But these advances give us hope that we’re moving closer to better options for mothers and babies.”

Key Facts About Preeclampsia

• Occurs in 3% to 8% of pregnancies globally, with higher rates in low-income countries.
• Symptoms include high blood pressure, protein in urine, severe headaches, vision changes, and swelling in the hands and face.
• Risk factors include first-time pregnancy, advanced maternal age, obesity, and preexisting conditions like diabetes or kidney disease.
• Complications can include placental abruption, organ failure, and eclampsia (seizures).
• Long-term, women with a history of preeclampsia have a 2- to 4-fold increased risk of heart disease and stroke.

If you or someone you know is pregnant and experiencing symptoms of preeclampsia, seek medical attention immediately. Early detection and management are critical to preventing severe outcomes.